(Press-News.org) Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented if a new drug, ticagrelor, was used instead of the standard treatment, clopidogrel.
Professor Storey's latest findings were presented at the British Cardiovascular Society annual scientific conference in Manchester today (Monday 13 June 2011).
Professor Storey has led UK investigations of ticagrelor and was a member of the international committee that conducted the PLATO study, a trial of over 18 thousand patients in over 40 countries around the world. The results of the PLATO study were first presented at the European Society of Cardiology congress in 2009, showing that ticagrelor was more effective for heart attack patients than clopidogrel in reducing death and recurrent heart attack.
A new analysis of the PLATO study presented this year at the American College of Cardiology showed that ticagrelor is just as effective at reducing deaths in patients over the age of 75 as in younger patients. Professor Storey commented: "Our new findings really highlight the universal applicability of the treatment."
Ticagrelor was made available in the UK in December 2010 but has not yet been adopted across most of the UK due to cost concerns. Clopidogrel has a very low cost as it is available in generic forms, whereas ticagrelor is more expensive at around £55 per month. However, the excess drug cost of ticagrelor is offset to some extent by its greater effectiveness which reduces the need for heart operations.
Professor Storey commented: "Many people are dying avoidably in the year after having a heart attack due to delays introducing this new treatment. These new findings provide yet further evidence in support of making the drug available to patients in the UK. We're pleased that the Scottish Medicine Consortium recently approved ticagrelor, on the basis that the initial expense of the drug is offset to a significant extent by the resultant savings, such as reduced need for procedures. In England, a verdict from NICE is awaited but final guidance is not expected until October."
One of the problems with clopidogrel is that about a quarter of people in the UK have a genetic variant that reduces the effect of the drug and are at greater risk. A sub-study of the PLATO trial was published in the Lancet confirming that patients treated with clopidogrel, who have such a genetic variant, have a slightly higher risk in the first month following heart attack but ticagrelor is not affected by this variant and is still more effective than clopidogrel, regardless of a patient's genetic make-up.
A common side-effect of ticagrelor is a sense of breathlessness which is usually mild and well-tolerated. Professor Storey presented data at the European Society of Cardiology meeting in 2010 showing that even patients who develop this side-effect still seem to have the reduced mortality risk compared to clopidogrel-treated patients. Another analysis led by Professor Storey showed that patients who develop breathlessness on ticagrelor do not show any problems on heart or lung tests, providing reassurance about the benign nature of ticagrelor-related breathlessness.
Professor Storey has been involved with the development of ticagrelor and related drugs for the past 15 years. 90 patients from Sheffield, with acute coronary syndrome, were recruited for the PLATO trial, which involved over 18,000 cardiac patients worldwide. One of the questions that is currently unanswered is whether continuing ticagrelor beyond 1 year after a heart attack will lead to continued benefit. This question will be addressed by the PEGASUS study which has recently started in the UK and many other countries, recruiting patients who are within 2 years of completing their one year course of treatment following a heart attack.
Professor Storey commented: "PEGASUS is an exciting study that will recruit 21,000 patients around the world, looking at whether ticagrelor added to aspirin is more effective at preventing problems related to clotting in the arteries than the standard anti-clotting treatment of aspirin only. Another study (ATLANTIC) planned to start in the next few months will also assess whether it is more effective to treat patients with full-blown heart attack with ticagrelor in the ambulance rather than wait until patients arrive at the hospital to have the blocked artery opened by balloon angioplasty."
###
Notes for editors:
Ticagrelor is manufactured by pharmaceutical company AstraZeneca in Leicestershire . It is licensed by the European Medicines Agency for use, in combination with aspirin, in patients with acute coronary syndromes; for more details see:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001241/WC500100494.pdf
To find out more about the Department of Cardiovascular Science, visit:
http://www.shef.ac.uk/cardiovascularscience
For further information please contact: Amy Stone, Media Relations Officer, on 0114 2221046 or email a.f.stone@sheffield.ac.uk
To view this news release and images online, visit http://www.shef.ac.uk/mediacentre/2011/new-heart-attack-drug.html
To read other news releases about the University of Sheffield, visit http://www.shef.ac.uk/mediacentre/
END
The number of heart attack deaths at Europe's sporting venues is set to significantly reduce if recommendations published today are widely adopted. In a special article published online today by the European Heart Journal (EHJ), minimum standards of cardiovascular medical expertise, available equipment, and emergency planning are defined for stadiums and mass participation events, including marathons and cycle sportives. The recommendations have been developed in response to a 2010 review¹ of cardiovascular safety at 190 major soccer arenas. This review determined that, ...
Researchers at Cincinnati Children's Hospital Medical Center have developed a tool to rapidly assess the risk of aggressive and violent behavior by children and adolescents hospitalized on psychiatric units. Ultimately, they hope to use the questionnaire to improve treatment and prevention of aggressive behavior in schools and in the community.
A study providing preliminary validation of the Brief Rating of the Child and Adolescent Aggression (BRACHA) tool is published online in the Journal of the American Academy of Psychiatry and the Law.
"Using the BRACHA could ...
Approximately 12 million people in the United States are cancer survivors. On average, their medical care costs $4,000 to $5,000 more annually than the care of people who have never had cancer, according to Penn State researchers.
Those who are treated for and survive cancer are susceptible to later health complications and their total medical expenses average about $9,300 per year. People are considered cancer survivors from the moment they are diagnosed through the end of their lives. Advances in medicine enable more people to survive cancer, but there is little information ...
The idea for this research arose when the problems of the large structural components of an airplane were being analyzed. These components are made up of a large number of different elements, which are themselves assembled using a variety of techniques, such as soldering, mechanical or adhesive bonding or a combination of these. Of these techniques, mechanical bonding is the method most commonly used in components made of composite materials. For example, the wing of an Airbus 380 alone is composed of over 30,000 elements, with approximately 750,000 bolted joints. These ...
NEW YORK, NY – June 13, 2011 – Data from the landmark HORIZONS-AMI clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a glycoprotein (GP) IIb/IIIa inhibitor in heart attack patients undergoing angioplasty after 3 years. Use of a drug-eluting stent (paclitaxel) was also shown to be more effective than a bare-metal stent, with equivalent safety. Final 3-year results of the trial were published in the June 13, 2011, issue of The Lancet.
After 3 years, treatment with bivalirudin ...
This release is available in French.
Montreal, June 13, 2011 – Exposure to secondhand smoke can create symptoms of nicotine dependence in non-smoking preteens, according to a new study from Concordia University and the University of Montreal.
Published in the Oxford journal Nicotine & Tobacco Research, the study also found that tweens who repeatedly observe a parent, sibling, friend or neighbor consuming cigarettes are more likely to light up themselves as adolescents.
"Kids who see others smoking are more likely to take up the habit because they don't perceive ...
Migraine is a neurovascular disease that affects about 15% of the western population. Compounds in foods and beverages (chocolate, wine, citrus, etc) considered as migraine triggers include tyramine, phenylethylamine and possibly histamine and phenolic compounds. Avoiding those triggers may significantly reduce the frequency of migraines in some patients.
However, only a small percentage of patients in one study became headache-free simply by excluding those foods, epidemiological studies are pointing out that genetic factors may be an underlying cause. Discrepancies ...
Contact: Dr. Abigail Stevenson
Abigail.Stevenson@effem.com
44-166-441-5409
Waltham Centre for Pet Nutrition
Waltham Centre for Pet Nutrition advances understanding of factors influencing body weight in cats
New research by the Waltham Centre for Pet Nutrition marks an important step forward in the fight against cat obesity
13th June, 2011 – A collaborative team of researchers has shown that adding moisture to a cat's diet slows down the rate of weight gain. This finding, at least in part, appeared to be driven by increased activity. This research was conducted at ...
Boston, Mass – Guidelines that reduce the use of mechanical ventilation with premature infants in favor of a gentler form of respiratory support can profoundly affect those children's outcomes while reducing the cost of care, according to a team of researchers at Children's Hospital Boston.
The team, led by Bernadette Levesque, MD, of the Division of Newborn Medicine at Children's Hospital Boston and the Neonatal Intensive Care Unit (NICU) at St. Elizabeth's Medical Center in Boston, published their findings today online in Pediatrics. Children's operates the NICU at ...
CAMBRIDGE, Mass. -- Photographs of moving objects are almost always a little blurry. To make their work look as much like conventional film as possible, game and movie animators try to reproduce this blur. But producing blurry images is actually more computationally complex than producing perfectly sharp ones.
In August, at this year's Siggraph conference — the premier computer-graphics conference — researchers from the Computer Graphics Group at MIT's Computer Science and Artificial Intelligence Laboratory will present a pair of papers that describe new techniques for ...
